Oregon is currently home to 1214 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Portland, Eugene, Medford and Clackamas. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
The Society for Obstetric Anesthesia and Perinatology Research Network General Anesthesia Registry
NCT06030063
Recruiting
The SOAP registry is a prospective, multicenter, electronic registry. The goal is to investigate the indications, mode of airway management, predisposing factors, and obstetric and anesthetic outcomes of pregnant patients who receive general anesthesia for cesarean delivery.
Gender:
FEMALE
Ages:
Between 15 years and 55 years
Trial Updated:
01/02/2025
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Cesarean Delivery, General Anesthesia
Register for Updates
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
NCT02915198
Recruiting
This research will help us to learn if the medicine called metformin reduces the risk of death, heart attacks, and/or strokes in Veterans who have pre-diabetes and heart or blood vessel problems.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: VA Portland Health Care System, Portland, OR, Portland, Oregon
Conditions: Prediabetic State, Atherosclerosis, Metformin
Register for Updates
Acute Immune Modulation by Probiotic Strain
NCT06754228
Recruiting
Clinical proof-of-concept study, comparing the acute immune impacts of 3 doses of a probiotic strain to a placebo. This study involves twenty-four participants, composed of healthy adults, who will be taking a placebo and 3 different doses of the probiotic at different times. Testing for immune status and cytokine levels will be conducted to determine the acute impact of the probiotic on immune function when compared to a placebo.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/23/2024
Locations: NIS Labs, Klamath Falls, Oregon
Conditions: Immune Surveillance
Register for Updates
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
NCT06470243
Recruiting
This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels (castrate-resistant) and that has spread from where it first started (primary site) to other places in the body (metastatic). Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by kill... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: Saint Alphonsus Cancer Care Center-Baker City, Baker City, Oregon
Conditions: Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Register for Updates
Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age
NCT05871970
Recruiting
This is a Phase 2a/b single arm open label study to evaluate the safety, reactogenicity, and efficacy of intracystic injection of TARA-002 in participants 6 months to less than 18 years of age for the treatment of macrocystic and mixed cystic lymphatic malformations. The Phase 2a safety lead-in, age de-escalation study is designed to establish the safety of TARA-002 in older participants 6 years to less than 18 years before proceeding to younger participants 2 years to less than 6 years, then 6... Read More
Gender:
ALL
Ages:
Between 6 months and 18 years
Trial Updated:
12/20/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Lymphatic Malformation
Register for Updates
Study of Navtemadlin Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT06479135
Recruiting
This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone. Subjects will start by receiving ruxolitinib alone in the run-in period. Those who demostrate a suboptimal response from ruxolitinib alone will then be randomized 2:1 to receive navtemadlin or navtemadlin placebo as add-on treatment to their ongoing ruxol... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Willamette Valley Cancer Institute and Research Center, Eugene, Oregon
Conditions: Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis, MF
Register for Updates
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
NCT05758493
Recruiting
This is a single center prospective study evaluating 124I-evuzumitide in patients with systemic amyloidosis. The purpose of this study is to 1)identify and characterize the distribution and uptake of 124I-evuzumitide in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and 2) Correlate the uptake with the structure and function of different organs, including the heart. To achieve these goals, eligible patients will undergo primarily hybrid positron emission tomography and magnetic res... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
12/18/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Amyloidosis, Transthyretin Amyloidosis
Register for Updates
Safety and Durability of Sirolimus for Treatment of LAM
NCT02432560
Recruiting
The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Lymphangioleiomyomatosis
Register for Updates
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05633615
Recruiting
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) for diffuse large B-cell lymphoma that has come back (recurrent) or that does not respond to treatment (refractory) or grade IIIb follicular lymphoma. Mosunetuzumab is a monoclonal antibody that may inter... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: Providence Newberg Medical Center, Newberg, Oregon
Conditions: Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
Register for Updates
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
NCT05443126
Recruiting
The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: Providence Portland Medical Centre, Portland, Oregon
Conditions: Advanced Solid Tumor
Register for Updates
Ruxolitinib in Treating Patients with Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
NCT03801434
Recruiting
This phase II trial studies how well ruxolitinib works in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Peripheral Blood White Cells, Blasts Under 20 Percent of Bone Marrow Nucleated Cells, Chronic Eosinophilic Leukemia, Not Otherwise Specified, Eosinophilia, Hepatomegaly, Hypereosinophilic Syndrome, JAK2 Gene Mutation, Splenomegaly, TEL-JAK2 Fusion Protein Expression
Register for Updates
Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Small Tonsils
NCT06258837
Recruiting
The purpose of this study is to compare the effectiveness of a novel personalized surgical approach to the standard AT in children with small tonsils (ST). This will be accomplished by randomizing children with ST and OSA to one of these two treatments and comparing outcomes after 6 months. It is the investigators' central hypothesis that a personalized drug-induced sleep endoscopy (DISE)-directed surgical approach that uses existing procedures to address the specific fixed and dynamic anatomic... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
12/16/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Otolaryngological Disease, Obstructive Sleep Apnea
Register for Updates